Age (years)
|
70.0 ± 9.9
|
66.9 ± 11.5
|
< 0.001
|
Age 65–74
|
210 (37.7%)
|
902 (31.1%)
|
0.002
|
Age ≥ 75
|
185 (33.2%)
|
813 (28.0%)
|
0.013
|
Male sex
|
371 (66.6%)
|
1,643 (56.6%)
|
< 0.001
|
Body weight (kg)
|
66.3 ± 13.9
|
66.1 ± 14.9
|
0.763
|
BMI (kg/m2)
|
25.1 ± 4.3
|
25.2 ± 4.8
|
0.767
|
Type of AF
|
Paroxysmal AF
|
188 (33.8%)
|
891 (30.7%)
|
0.152
|
Persistent/permanent AF
|
353 (63.4%)
|
1,938 (66.7%)
|
0.125
|
CHA2DS2VASc score
|
4.17 ± 1.53
|
2.78 ± 1.60
|
< 0.001
|
Non-gender CHA2DS2-VASc score
|
3.84 ± 1.41
|
2.34 ± 1.48
|
< 0.001
|
Non-gender CHA2DS2-VASc score 0–1
|
20 (3.6%)
|
877 (30.2%)
| |
Non-gender CHA2DS2-VASc score of 2 or more
|
537 (96.4%)
|
2,027 (69.8%)
| |
HAS-BLED score
|
2.01 ± 1.01
|
1.45 ± 0.98
|
< 0.001
|
Non-antiplatelet HAS-BLED score
|
1.43 ± 0.90
|
1.24 ± 0.96
|
< 0.001
|
Comorbidities
| | | |
History of heart failure
|
217 (39.0%)
|
706 (24.3%)
|
< 0.001
|
NYHA class
| | |
0.288
|
I
|
58 (26.7%)
|
239 (33.9%)
| |
II
|
125 (57.6%)
|
371 (52.5%)
| |
III
|
23 (10.6%)
|
56 (7.9%)
| |
IV
|
3 (1.4%)
|
9 (1.3%)
| |
LVEF (%)
|
54.4 ± 17.1
|
61.0 ± 14.0
|
< 0.001
|
Hypertension
|
416 (74.7%)
|
1,948 (67.1%)
|
< 0.001
|
Diabetes mellitus
|
205 (36.8%)
|
645 (22.2%)
|
< 0.001
|
History of TIA/stroke
|
81 (14.5%)
|
521 (17.9%)
|
0.053
|
PAD
|
17 (3.1%)
|
28 (1.0%)
|
< 0.001
|
History of major bleeding
|
15 (22.7%)
|
57 (21.8%)
|
0.865
|
Intracranial hemorrhage
|
1 (6.7%)
|
18 (31.6%)
|
0.096
|
GI hemorrhage
|
11 (73.3%)
|
26 (45.6%)
|
0.056
|
Chronic kidney disease
|
eGFR (mL/min)
|
48.5 ± 20.0
|
57.4 ± 21.2
|
< 0.001
|
GFR < 60 mL/min
|
333 (73.7%)
|
1,254 (59.0%)
|
< 0.001
|
On renal replacement therapy
|
17 (3.1%)
|
23 (0.8%)
|
< 0.001
|
Chronic liver disease
|
13 (2.3%)
|
68 (2.3%)
|
0.991
|
Labile INR
|
171 (30.7%)
|
724 (24.9%)
|
0.004
|
CIED
|
82 (14.7%)
|
263 (9.1%)
|
< 0.001
|
Pacemaker
|
51 (62.2%)
|
222 (84.4%)
|
< 0.001
|
ICD/CRT-D
|
31 (37.8%)
|
40 (15.2%)
|
< 0.001
|
CRT-P/CRT-D
|
9 (11.0%)
|
8 (3.0%)
|
0.007
|